Literature DB >> 17377926

Cognitive-behavioral therapy for depression in Parkinson's disease: a pilot study.

Roseanne DeFronzo Dobkin1, Lesley A Allen, Matthew Menza.   

Abstract

The present study was conducted to examine the feasibility and effect of an individual cognitive-behavioral treatment (CBT) for depression that was modified to meet the unique needs of the PD patient and incorporated a separate social support intervention for caregivers. Fifteen PD patients with Major Depressive Disorder participated in the study with a caregiver. Patients received 10-14 sessions of modified individual CBT. Caregivers attended 3-4 psychoeducational sessions, occurring separately from the patients treatment sessions, which focused on strategies for offering appropriate support, and ways to respond to the patients' negative thoughts in a targeted manner. Patients experienced a significant reduction in depressive symptoms and negative cognitions, and an increased perception of social support over the course of treatment. Gains were maintained at 1-month follow-up. In conclusion, individual CBT, when modified appropriately, may be a feasible and effective option for PD depression. Larger, randomized controlled trials are needed to further evaluate the efficacy of this intervention and to identify specific mechanisms of change. (c) 2007 Movement Disorder Society.

Entities:  

Mesh:

Year:  2007        PMID: 17377926     DOI: 10.1002/mds.21455

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  23 in total

1.  Apathy and depression: separate factors in Parkinson's disease.

Authors:  Lindsey Kirsch-Darrow; Michael Marsiske; Michael S Okun; Russell Bauer; Dawn Bowers
Journal:  J Int Neuropsychol Soc       Date:  2011-11       Impact factor: 2.892

Review 2.  Parkinson's disease: the quintessential neuropsychiatric disorder.

Authors:  Daniel Weintraub; David J Burn
Journal:  Mov Disord       Date:  2011-05       Impact factor: 10.338

3.  Cognitive-behavioral therapy for depression in Parkinson's disease: a randomized, controlled trial.

Authors:  Roseanne D Dobkin; Matthew Menza; Lesley A Allen; Michael A Gara; Margery H Mark; Jade Tiu; Karina L Bienfait; Jill Friedman
Journal:  Am J Psychiatry       Date:  2011-06-15       Impact factor: 18.112

Review 4.  The role of dopamine agonists in the treatment of depression in patients with Parkinson's disease: a systematic review.

Authors:  Albert F G Leentjens
Journal:  Drugs       Date:  2011-02-12       Impact factor: 9.546

Review 5.  Depression in Parkinson disease--epidemiology, mechanisms and management.

Authors:  Dag Aarsland; Sven Påhlhagen; Clive G Ballard; Uwe Ehrt; Per Svenningsson
Journal:  Nat Rev Neurol       Date:  2011-12-26       Impact factor: 42.937

Review 6.  Depressive syndromes in neurological disorders.

Authors:  Julian Hellmann-Regen; Dominique Piber; Kim Hinkelmann; Stefan M Gold; Christoph Heesen; Carsten Spitzer; Matthias Endres; Christian Otte
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-11       Impact factor: 5.270

7.  Telephone-based cognitive-behavioral therapy for depression in Parkinson disease.

Authors:  Roseanne D Dobkin; Matthew Menza; Lesley A Allen; Jade Tiu; Jill Friedman; Karina L Bienfait; Michael A Gara; Margery H Mark
Journal:  J Geriatr Psychiatry Neurol       Date:  2011-12       Impact factor: 2.680

Review 8.  [Depression and neurological diseases].

Authors:  D Piber; K Hinkelmann; S M Gold; C Heesen; C Spitzer; M Endres; C Otte
Journal:  Nervenarzt       Date:  2012-11       Impact factor: 1.214

9.  Palliative care in Parkinson's disease: role of cognitive behavior therapy.

Authors:  Samput Mallick
Journal:  Indian J Palliat Care       Date:  2009-01

10.  Parkinson's family needs and caregiver mental health: A cross-cultural comparison between Mexico and the United States.

Authors:  Paul B Perrin; Richard S Henry; Emily K Donovan; Annahir N Cariello; Sarah K Lageman; Teresita Villaseñor; Joseph M Dzierzewski; Monica Arroyo; Judith Avila
Journal:  NeuroRehabilitation       Date:  2019-12-18       Impact factor: 2.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.